IN PARTNERSHIP WITH CSI FIRST ANNOUNCEMENT Apr.14-16, 2017 Hangzhou, China SPONSOR Second Affiliated Hospital, Zhejiang University School of Medicine CO-SPONSOR CSI (Catheter Interventions in Congenital, Structural and Valvular Heart Disease)
WELCOMING REMARKS Dear colleagues and friends, Incidence of valvular heart diseases keeps increasing along with the aging trend of the world, and makes it a serious threat to human health. As the evidence accumulates, transcatheter valvular replacement or repair emerged as an alternative for traditional cardiac surgery, especially in the field of transcatheter aortic valve replacement (TAVR). However, development of transcatheter valvular treatment in China is still at the initial status. There is an urgent call for systemic training for Chinese interventional cardiologists and their heart valve teams. To improve transcatheter valvular treatment in China and international collaboration in the field, the third China Valve (Hangzhou) congress will be held on 14th to 16th April 2017. This year, we will continuously work with the support of CSI to provide a broader global vision, an improved training course and a deeper communicative platform. The program will include step by step learning from recorded cases, live cases, hands-on sessions, imaging training, up-to-date clinical trials and debates on hot spots, etc. Hangzhou is an ancient, yet highly civilized city rich in both historical sites and natural landscapes, such as the West Lake and Grand Canal. The city is also an international metropolis where the G20 summit held in September 2016. You will have the opportunity to enjoy the wonderful scenery after scientific activities. Welcome to Hangzhou! Course Chairman: Junbo Ge Course Directors: Jian an Wang Horst Sievert
ORGANIZATION Honorable Chairmen Runlin GAO Yong HUO (Beijing, China) (Beijing, China) Course Chairman Junbo GE (Shanghai, China) Course Directors Jian an WANG Horst SIEVERT (Zhejiang, China) (Course director of CSI, Germany)
ORGANIZATION International Faculties (In Alphabetic Order) Anthony DEMARIA (UCSD Medical Center, USA) Khalil FATTOUCH (Maria Eleonora Hospital, Italy) Ulrich GERCKENS (Gemeinschaftskrankenhaus, Bonn, Germany) Robert GOOLEY (MonashHEART, Australia) Eberhard GRUBE (Siegburg Heart Center, Germany) Kentaro HAYASHIDA (Keio University, Japan) Dongming HOU (USA) Hasan JILAIHAWI (NYU Langone Medical Center, USA) Patrizio LANCELLOTTI (University of Liège, Belgium) Thomas MODINE (Lille University Hospital, France) Duk-Woo PARK (ASAN Medical Center Korea) Advisory Committee (In Alphabetic Order) Daniel Tai-Leung CHAN (Queen Mary Hospital, Hong Kong) Yundai CHEN (Beijing, China) Dejia HUANG (Sichuan, China) Michael Kang-yin LEE (Queen Elizabeth Hospital, Hongkong) Yat-Yin LAM(Hongkong Society of Congenital and Structural Heart Disease) Bo XU (Beijing, China) Wei-Hsian YIN (Cheng-Hsin General Hospital, Taiwan) Daxin ZHOU (Shanghai, China) Mao CHEN (Sichuan, China) Yaling HAN (Shenyang, China) Xiangqing KONG (Jiangsu, China) Simon Cheung-Chi LAM (Queen Mary Hospital, Hong Kong) Yongjian WU (Beijing, China) Yuejing YANG (Beijing, China) Ruiyan ZHANG (Shanghai, China) Scientific Committee (In Alphabetic Order) Jiyan CHEN (Guangdong, China) Xiaoshu CHEN (Jiangxi, China) Yingqiang GUO (Sichuan,China) Guoqing LI (Xinjiang, China) Genshan MA (Jiangsu, China) Yongwen QIN(Shanghai, China) Yong SUN (Zhejiang, China) Hongju WANG (Anhui, China) Qiang WU (Guizhou, China) Meixiang XIANG (Zhejiang, China) Bo YU (Heilongjiang, China) Zuyi YUAN (Shanxi, China) Xianxian ZHAO (Shanghai, China) Shaoliang CHEN (Jiangsu, China) Yuan FENG (Sichuan, China) Ben HE (Shanghai, China) Xianhe LIN (Anhui, China) Yitong MA (Xinjiang, China) Xi SU (Hubei, China) Ling TAO (Shanxi, China) Yan WANG (Fujian, China) Yanqing WU (Jiangxi, China) Biao XU (Jiangsu, China) Zaixin YU (Hunan, China) Heng ZHANG (Anhui, China) Secretariats Jun JIANG (Zhejiang, China) Xianbao LIU (Zhejiang, China)
PROGRAM DRAFT April 14 Friday Main Arena Session 1: 13:30-15:00 Learning from recorded TAVR case step by step Clinical evaluation Echocardiographic evaluation CT analysis Heart valve team discussion (cardiologist, surgeon, anesthesiologist, radiologist, nurse etc.) Recorded TAVR case step by step Session 2: 15:30-16:30 Optimising TAVR outcomes Clinical situation: where are the limits How to evaluate and get vascular access safely How to choose correct THV and valve size Double S curve guided deployment Session 3: 17:00-18:00 Making TAVR simple? Local or general anesthesia? TTE or TEE guidance? Hybrid or ordinary catheter room? Will TAVR be performed as PCI in the future? Heart valve team will be changed in the future? Room 3 Hands on training How to perform transcatheter self-expanding aortic valve with VENUS A How to perform transcatheter mechanical-expanding Lotus valve April 15 Saturday Main Arena Session 4 08:00-09:00 Moving farward to lower risk patients What s the real difference between high risk and lower risk patients The limitations of surgery in lower risk patient-perspectives from interventionalist The limitations of TAVR in lower risk patient-perspectives from surgeon Latest evidence and limitations
PROGRAM DRAFT April 15 Saturday Main Arena 09:00-09:30 Opening ceremony Session 5 09:30-10:30 Dialogues of TAVR between China and the world Current status Bicuspid aortic valve Severe calcification and thickened leaflets Home-made devices and new generation devices Perspectives from cardiologists and surgeons Session 6 10:30-12:30 Live cases Session 7 13:30-15:00 Long term outcomes and bioprothetic valve durability Controversies of TAVR bioprostheses deterioration Why might TAVR bioprotheses fail Lessons from surgical experience Subclinical thrombosis and leaflet thickening TAV in TAV: current status and future TAVR for younger patients: my thinking Session 8 15:00-17:00 Live cases Session 9 17:00-18:00 Percutaneous mitral and tricuspid valves intervention Anatomic challenges Update of transcatheter mitral valve replacement or repair Current status of percutaneous tricuspid valve intervention Experience from China Room 2 Session1 13:30-15:30 TAVR for bicuspid aortic valve Anatomic characteristics and procedural considerations What guideline say and up-to-date outcomes of clinical studies Advantages and disadvantages of different transcatheter heart valves Sizing strategy and outcomes - experience from China Cases Session2 16:00-18:00 International challenging TAVR cases
PROGRAM DRAFT Room 3 Hands on training How to perform transcatheter self-expanding aortic valve with VENUS A How to perform transcatheter mechanical-expanding Lotus valve April 16 Sunday Main Arena Session 10 08:00-09:00 How to design TAVR clinical studies and get published Session 11 09:00-10:30 Management of complications-1 Case 1 PVL How to prevent and treat PVL Case 2 vascular complication How to prevent and treat vascular complications Case 3 conduction disturbance Predictors of conduction disturbance and how to minimize PPM Session 12 10:30-12:00 Management of complications-2 Case 4 stroke Predictors of stroke and prevention Case 5 Coronary obstruction How to prevent and treat coronary obstructions Case 6 annulus rupture or myocardial perforation How to prevent and treat annulus rupture or myocardial perforation Room 3 Hands on training How to perform transcatheter self-expanding aortic valve with VENUS A How to perform transcatheter mechanical-expanding Lotus valve
CONFERENCE INFORMATION Conference Venue Address The Dragon Hotel, Hangzhou, China 120 Shuguang Road, Hangzhou, China 310007 Hotel Tel +86 400 600 0676 Website www.china-valve.org.cn Pre-registration on line up to 31st March, 2017 Pre-registration Fee 800 Registration on the spot Registration Fee Contacts Tel 1000 Qiyuan Xu Yan Lin +86 158 6904 9557 Email 14th to 15th April, 2017 +86 187 6811 5530 CVH2017@ china-valve.org.cn